COMPANY PROFILE

Ionpath

Explore full profile

Enabling precision medicine through high-definition spatial proteomics

Menlo Park, United StatesFounded 2014Health Tech & Medtech

Valuation $100–250M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Ionpath

Ionpath, Inc. operates in the biotechnology sector, specializing in high definition spatial proteomics. The company has developed a multiplexed ion beam imaging (MIBI) platform that surpasses traditional immunohistochemistry (IHC) methods. This platform enables researchers and clinicians to gain a deeper understanding of the tissue microenvironment through highly multiplexed, quantitative single cell analysis. Ionpath's technology is particularly valuable for identifying responder populations, predicting patient responses, and informing therapeutic selection. The company's primary clients include academic research institutions, pharmaceutical companies, and clinical laboratories. Ionpath generates revenue through the sale of its imaging platforms, consumables, and related services. The market it operates in is the rapidly growing field of precision medicine and advanced diagnostics.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Menlo Park, United States
Employees: 11
Open positions: None listed
Dealroom signal: 63.5/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Core AI, Precision Medicine, Spinout, AI Applications, proteomics, DT and LS, science-based
Technology: Artificial Intelligence, Deep Tech, Computer Vision
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	May 2022	$0	—	Thermo Fisher Scientific	↗
SERIES B✓Equity / VC	Sep 2020	$18M	$72M	+ND Capital · Genoa Ventures · Samsara BioCapital · Bruker	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Ionpath website traffic

Latest recorded traffic for Ionpath is 1.1K monthly website visits, up 120% over the last three months. Ionpath's team declined 21.4% over the past year.

Latest monthly visits1.1K 3-month web change+120% 1-year team growth-21.4%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
KLKAZAAM LabProvides useful software services to extract hidden information within heterogeneous biomedical big data	Partinico, Italy	Operational	3	$55K	—
SUSurgeInnovative fingerprinting of the immune system with AI to holistically improve the perioperative standard-of-care	Paris, France	Operational
PIPixylNeuroimaging AI for Improved Patient Care	La Tronche, France	Acquired
INInterVennCombines next generation epiproteomics, instrumentation, and deep learning to augment cancer diagnosis, biomarker, and target discovery	South San Francisco, United States	Operational
DEDeepcellAims to provide detailed genetic health information through ordinary blood sampling	Sunnyvale, United States	Operational
IBInterAx BiotechDelivering High-Quality Drug Candidates for GPCR Targets	Villigen, Switzerland	Operational
TNTS NanoNanotechnology solutions for cancer and virus detection using AI and machine learning	Melbourne, Australia	Operational
NANucs AIAdvanced AI-driven solutions that deliver precise, actionable insights for the clinical management of prostate cancer, empowering healthcare professionals	San Francisco, United States	Operational